investor relations
NASDAQ: current stock price
| Price | $19.80 |
|---|---|
| Volume | 329,082 |
| Intraday High | $19.95 |
| Intraday Low | $19.30 |
| Today's Open | $19.30 |
press releases
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide...
MoreData on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conferenc...
MoreNovocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European S...
MoreNovocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
MoreFirst Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevaciz...
MoreCombination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Severa...
MoreNovocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Glio...
MoreNovocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Qua...
MoreNovocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurolo...
MoreCNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line...
MoreCombination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Ye...
MoreCombination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent...
MoreCombination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine...
MoreNovocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with St...
MoreNovocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting...
MoreNovocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update
MoreFirst Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for...
MoreNovocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblas...
MoreNovocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fiel...
MoreNovocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclita...
MoreLong-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagn...
MoreNovocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields P...
MoreNovocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st ...
MoreNovocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of th...
MoreCNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in ...
MoreNovocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academ...
More
events
Novocure at the Bio€quity Europe 2017 Conference
View PresentationNovocure at the Deutsche Bank 42nd Annual Health Care Conference
View Presentation Listen to WebcastNovocure at the 13th Annual Noble Capital Markets Investor Conference
View Presentation Listen to WebcastNovocure Research and Development Day
View Presentation
stock information
See our current stock performance, trading data and historical pricing information (NASDAQ: NVCR).
Learn More
FAQs
- What is the ticker symbol for Novocure?
Shares of Novocure are traded on the NASDAQ Global Select Stock Market under the ticker symbol NVCR.
- When did Novocure go public?
Novocure started trading publicly on October 2, 2015.
- Where is Novocure's corporate headquarters?
Novocure is headquartered in the Bailiwick of Jersey.
- When does Novocure's fiscal year end?
December 31.
- Who is Novocure's transfer agent?
Our transfer agent is Computershare Shareowner Services LLC. There are a number of ways to contact Computershare to access information in connection with your account. Note: you will need to supply your tax identification number and contact information, including address.
Investor Centre™ website:
Manage your account online via Computershare’s secure Web-based shareholder tool at http://www.computershare.com/investor. Through free, around-the-clock access to the website, you can:
- View your account details and update account information
- Access tax forms
- Request certificates
- Enroll in eDelivery to receive shareholder materials electronically
Telephone inquiries:
+1 (877) 373-6374 (US, Canada, Puerto Rico)
+1 (781) 575-3100 (non-US)Written requests:
By regular mail:
Computershare
P.O. Box 43070
Providence, RI 02940-3070By overnight delivery:
Computershare
250 Royall Street
Canton, MA 02021- How do I change the address on my stockholder account?
If you own shares through a brokerage firm, you need to contact that firm directly to change your account address.
If you own shares in the form of a stock certificate, you may update your address by contacting our transfer agent, Computershare Shareowner Services LLC, at 877-419-8459 or via their website at https://www-us.computershare.com/investor.
- How can I buy Novocure stock?
Shares can be purchased through a stockbroker of your choice. Novocure does not have a direct stock purchase program.
- What is Novocure's CUSIP number?
Our ordinary shares CUSIP number is G6674U 108.
- Who are the independent auditors?
Kost Forer Gabbay & Kasierer
A member of Ernst & Young Global
Tel-Aviv, Israel
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.
-
about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
-
our therapy
- mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.
- delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.
- treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
-
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
- patient-forward
- news and media
- investor relations
- careers